RxDoctor Payments Data

Sonia Reich

Nurse Practitioner · Milton, PANPI 1821377227

Payments from drug & device makers

$3,692in general payments, 2019–2025

Across 191 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$693
  • AbbVie$570
  • GSK$449
  • AstraZeneca$368
  • Novo Nordisk$341
  • Boehringer Ingelheim$316
  • plus $954 from 14 others

What the payments were for

  • Food & beverage$3,692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,692 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,616
Medicare patients
152
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$100,560
EliquisApixaban106$81,205
JardianceEmpagliflozin74$70,546
XareltoRivaroxaban48$46,013
MounjaroTirzepatide20$20,276
LinzessLinaclotide17$14,522
Spiriva RespimatTiotropium Bromide12$9,865
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$9,609
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,591
TradjentaLinagliptin14$9,488
FarxigaDapagliflozin Propanediol13$8,998
Varenicline Tartrate27$7,677
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$6,568
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,019
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14$5,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$341$100,56085 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Tradjenta$316$99,507115 claims
PfizerEliquis$127$81,205106 claims
Johnson & JohnsonXarelto$196$46,01348 claims
Lilly USA, LLCMounjaro$693$20,27620 claims
GSKTrelegy Ellipta, Anoro Ellipta$449$15,61028 claims
AstraZenecaFarxiga, Bevespi Aerosphere$368$14,73127 claims
AbbVieLinzess$570$14,52217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Milton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →